Published in Int J Cancer on February 09, 1999
Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. Chem Res Toxicol (2011) 1.38
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs (2007) 0.94
Quantifying exploratory low dose compounds in humans with AMS. Adv Drug Deliv Rev (2010) 0.84
Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis (2010) 0.79
Stability and reactivity of 2-nitrosoamino-3,8-dimethylimidazo[4,5-f]quinoxaline. Chem Res Toxicol (2006) 0.78
Quantitative metabolism using AMS: Choosing a labeled precursor. Nucl Instrum Methods Phys Res B (2010) 0.76
Disposition of the Dietary Mutagen 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline in Healthy and Pancreatic Cancer Compromised Humans. Chem Res Toxicol (2016) 0.76
Microdose-induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther (2016) 0.75
Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology. Chem Res Toxicol (2016) 0.75
Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res (1972) 2.18
Increased susceptibility to carbon tetrachloride poisoning in the rat after pretreatment with oral phenobarbitone. Biochem Pharmacol (1969) 2.15
Correlation of DNA adduct levels in human lung with cigarette smoking. Nature (1989) 1.86
Aflatoxin B -oxide generated by chemical or enzymic oxidation of aflatoxin B1 causes guanine substitution in nucleic acids. Nature (1977) 1.76
Deranged liver blood flow patterns in the detection of liver metastases. Br J Surg (1985) 1.73
Accelerator mass spectrometry. Anal Chem (1995) 1.55
Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis (2003) 1.54
Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis (2005) 1.53
Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis (2007) 1.53
Testing of some azo dyes and their reduction products for mutagenicity using Salmonella typhimurium TA 1538. Mutat Res (1977) 1.51
DNA adducts in different tissues of smokers and non-smokers. Int J Cancer (1990) 1.48
The measurement of limb blood flow using technetium-labelled red blood cells. Br J Radiol (1986) 1.42
Safe sects? Dynamic religion and AIDS in South Africa. J Mod Afr Stud (2000) 1.38
Benign axillary epithelial lymph node inclusions--a histological pitfall. Histopathology (1988) 1.24
DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Epidemiol Biomarkers Prev (1999) 1.21
Determination of 8-oxoguanine in DNA by gas chromatography--mass spectrometry and HPLC--electrochemical detection: overestimation of the background level of the oxidized base by the gas chromatography--mass spectrometry assay. Chem Res Toxicol (1995) 1.19
A high pressure liquid chromatography study on the removal of DNA-bound aflatoxin B1 in rat liver and in vitro. Carcinogenesis (1980) 1.19
Microsome-dependent binding of aflatoxin B1 to DNA, RNA, polyribonucleotides and protein in vitro. Chem Biol Interact (1973) 1.18
Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res (1995) 1.18
Improving the detection of hepatic metastases by the use of dynamic flow scintigraphy. Br J Cancer (1983) 1.18
Induction of mutations in DNA-repair deficient bacteria by a liver microsomal metabolite of aflatoxin B1. Br J Cancer (1973) 1.17
Identification of N-(Deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine as the major adduct formed by the food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, with DNA. Chem Res Toxicol (1992) 1.17
Heterocyclic aromatic amine formation in grilled bacon, beef and fish and in grill scrapings. Carcinogenesis (1993) 1.15
Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis (1986) 1.14
Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine to intermediates which bind DNA. Mutat Res (1990) 1.14
In vivo dosimetry of 4-aminobiphenyl in rats via a cysteine adduct in hemoglobin. Cancer Res (1984) 1.10
Attomole detection of 3H in biological samples using accelerator mass spectrometry: application in low-dose, dual-isotope tracer studies in conjunction with 14C accelerator mass spectrometry. Chem Res Toxicol (1998) 1.07
Solution structure of the 2-amino-1- methyl-6-phenylimidazo[4,5-b]pyridine C8-deoxyguanosine adduct in duplex DNA. Proc Natl Acad Sci U S A (2001) 1.06
Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Cancer Lett (1999) 1.05
Quantitative determination of polycyclic aromatic hydrocarbons in barbecued meat sausages by gas chromatography coupled to mass spectrometry. J Agric Food Chem (2000) 1.04
Metabolism of food-derived heterocyclic amines in nonhuman primates. Mutat Res (1997) 1.01
Smoking-related DNA adducts in human gastric cancers. Int J Cancer (1992) 1.01
Comparison of aflatoxin B1 and aflatoxin G1 binding to cellular macromolecules in vitro, in vivo and after peracid oxidation; characterisation of the major nucleic acid adducts. Chem Biol Interact (1979) 0.98
Binding of [-14C]aflatoxin B1 to cellular macromolecules in the rat and hamster. Chem Biol Interact (1975) 0.98
Comparative biotransformation studies of MeIQx and PhIP in animal models and humans. Cancer Lett (1999) 0.97
Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene. Mutat Res (2000) 0.97
Characterisation of the imidazole ring-opened forms of trans-8,9-dihydro-8,9-dihydro-8-(7-guanyl)9-hydroxy aflatoxin B1. Carcinogenesis (1982) 0.97
Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine. Anal Chem (1998) 0.97
Production of monoclonal antibodies to guanine imidazole ring-opened aflatoxin B1DNA, the persistent DNA adduct in vivo. Carcinogenesis (1982) 0.96
Testing of some benzidine analogues for microsomal activation to bacterial mutagens. Cancer Lett (1975) 0.96
Methods of DNA adduct determination and their application to testing compounds for genotoxicity. Environ Mol Mutagen (2000) 0.95
Tissue distribution and macromolecular binding of extremely low doses of [14C]-benzene in B6C3F1 mice. Carcinogenesis (1997) 0.95
Metabolism of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in human hepatocytes: 2-amino-3-methylimidazo[4,5-f]quinoxaline-8-carboxylic acid is a major detoxification pathway catalyzed by cytochrome P450 1A2. Chem Res Toxicol (2001) 0.95
Determination of in vitro formed DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine using capillary liquid chromatography/electrospray ionization/tandem mass spectrometry. Chem Res Toxicol (1995) 0.95
Determination of in vitro- and in vivo-formed DNA adducts of 2-amino-3-methylimidazo[4,5-f]quinoline by capillary liquid chromatography/microelectrospray mass spectrometry. Chem Res Toxicol (1999) 0.95
Formation of a factor lethal for S. typhimurium TA1530 and TA1531 on incubation of aflatoxin B 1 with rat liver microsomes. Biochem Biophys Res Commun (1971) 0.95
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs (2007) 0.94
Qualitative and quantitative characterization of mutagens in commercial beef extract. Carcinogenesis (1983) 0.94
Chemical analysis, prevention, and low-level dosimetry of heterocyclic amines from cooked food. Cancer Res (1992) 0.93
Metabolism of ochratoxin A: absence of formation of genotoxic derivatives by human and rat enzymes. Chem Res Toxicol (2001) 0.93
The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure. Food Chem Toxicol (2004) 0.92
Comparison of analytical techniques to quantify malondialdehyde in milk powders. J Chromatogr A (2001) 0.92
MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat Res (1997) 0.91
Accelerator mass spectrometry as a bioanalytical tool for nutritional research. Adv Exp Med Biol (1998) 0.91
Mutagenicity of methyl-, ethyl-, propyl- and butylnitrosourea towards Escherichia coli WP2 strains with varying DNA repair capabilities. Chem Biol Interact (1979) 0.91
Separation of haem incorporation from protein synthesis in liver microsomes. Biochem Biophys Res Commun (1969) 0.91
Dose-dependent binding of ortho-phenylphenol to protein but not DNA in the urinary bladder of male F344 rats. Toxicol Appl Pharmacol (1999) 0.90
Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification. Toxicol Lett (1998) 0.90
Glucuronidation of N-hydroxy heterocyclic amines by human and rat liver microsomes. Carcinogenesis (1994) 0.90
Attomole quantitation of protein separations with accelerator mass spectrometry. Electrophoresis (2001) 0.90
Testing of known carcinogens and noncarcinogens for their ability to induce unscheduled DNA synthesis in HeLa cells. Cancer Res (1978) 0.89
Metabolism of the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline in nonhuman primates undergoing carcinogen bioassay. Chem Res Toxicol (1993) 0.89
Reduction in binding of [14C] aflatoxin B1 to rat liver macromolecules by phenobarbitone pretreatment. Biochem Pharmacol (1975) 0.89
Effect of increased intake of vitamin C on the mutagenic activity of gastric juice and intragastric concentrations of ascorbic acid. Carcinogenesis (1985) 0.88
Covalent binding of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline to albumin and hemoglobin at environmentally relevant doses. Comparison of human subjects and F344 rats. Drug Metab Dispos (1998) 0.88
Studies on the detoxication of microsomally-activated aflatoxin B1 by glutathione and glutathione transferases in vitro. Carcinogenesis (1985) 0.88
Sulfamate formation is a major route for detoxification of 2-amino-3-methylimidazo[4,5-f]quinoline in the rat. Carcinogenesis (1986) 0.88
Leukocyte adherence inhibition: an automated microassay demonstrating specific antigen recognition and blocking activity in two murine tumor systems. J Immunol Methods (1977) 0.88
Chemical evidence for the formation of a reactive aflatoxin B1 metabolite, by hamster liver microsomes. FEBS Lett (1973) 0.88
Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clin Cancer Res (1996) 0.88
Distal femoropopliteal bypass using a composite graft of PTFE and non-reversed saphenous vein. Ann R Coll Surg Engl (1989) 0.87
Synthesis and spectroscopic characterization of site-specific 2-amino-1-methyl-6-phenylimidazo. Nucleic Acids Res (2001) 0.87
7-Alkyldeoxyguanosine adduct detection by two-step HPLC and the 32P-postlabeling assay. Carcinogenesis (1993) 0.87
The evaluation of blood flow measurement using gravimetric plethysmograph. Br J Surg (1980) 0.86
Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci (2003) 0.86
Metabolism of the food-borne mutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in humans. Chem Res Toxicol (1998) 0.86
A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. Cancer Epidemiol Biomarkers Prev (1997) 0.85
In vivo human metabolism of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Cancer Lett (1999) 0.85
Structure of the single stable hemoglobin adduct formed by 4-aminobiphenyl in vivo. Chem Res Toxicol (1992) 0.85
The identification of [2-(14)C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine metabolites in humans. Carcinogenesis (1999) 0.85
Characterization of a peptide adduct formed by N-acetoxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a reactive intermediate of the food carcinogen PhIP. Food Chem Toxicol (2004) 0.85
Biomonitoring of possible human exposure to environmental genotoxic chemicals: lessons from a study following the wreck of the oil tanker Braer. Environ Mol Mutagen (1997) 0.85